Skip to main content
Erschienen in: Diabetologia 5/2019

01.03.2019 | Article

Cellular proliferation in mouse and human pancreatic islets is regulated by serpin B13 inhibition and downstream targeting of E-cadherin by cathepsin L

verfasst von: Chi-Wen Lo, Yury Kryvalap, Tzong-jen Sheu, Ching-Ho Chang, Jan Czyzyk

Erschienen in: Diabetologia | Ausgabe 5/2019

Einloggen, um Zugang zu erhalten

Abstract

Aims/hypothesis

We previously reported that exposure to antibodies neutralising serpin B13, a protease inhibitor expressed in exocrine pancreatic ducts, promotes beta cell proliferation, underscoring the importance of a functional relationship between exocrine and endocrine pancreas. The aim of the present study was to identify the molecular events that link inhibition of serpin B13 to islet cell proliferation.

Methods

We used an in vitro culture system consisting of isolated pancreatic islets, an extract of pancreatic ductal epithelium and a monoclonal antibody (mAb) to serpin B13 or IgG isotype control. In vivo studies involved treatment of mice with these mAbs.

Results

The catalytic activity of cathepsin L (CatL), a cysteine protease target of serpin B13, was augmented in the pancreas of mice injected with serpin B13 mAb. Furthermore, the addition of serpin B13 mAb to the islets, together with the pancreatic ductal epithelium lysate, caused CatL-dependent cleavage of E-cadherin and concomitant upregulation of REG genes, ultimately leading to beta cell proliferation. Direct blockade of E-cadherin with mAb also markedly enhanced REG gene induction, while chemical inhibition of β-catenin, a binding target of E-cadherin, prevented the serpin B13 mAb-induced upregulation of REG genes.

Conclusions/interpretation

Our work implicates the CatL–E-cadherin–REG pathway in the regulation of islet cell proliferation in response to signals generated in exocrine pancreatic tissue and demonstrates that protease activity may promote adaptive changes in the islets.

Data availability

Microarray data that support the findings of this study have been deposited in Gene Expression Omnibus (GEO) with the accession no. GSE125151.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
6.
Zurück zum Zitat Kryvalap Y, Lo CW, Manuylova E, Baldzizhar R, Jospe N, Czyzyk J (2016) Antibody response to serpin B13 induces adaptive changes in mouse pancreatic islets and slows down the decline in the residual beta cell function in children with recent onset of type 1 diabetes mellitus. J Biol Chem 291(1):266–278. https://doi.org/10.1074/jbc.M115.687848 CrossRefPubMed Kryvalap Y, Lo CW, Manuylova E, Baldzizhar R, Jospe N, Czyzyk J (2016) Antibody response to serpin B13 induces adaptive changes in mouse pancreatic islets and slows down the decline in the residual beta cell function in children with recent onset of type 1 diabetes mellitus. J Biol Chem 291(1):266–278. https://​doi.​org/​10.​1074/​jbc.​M115.​687848 CrossRefPubMed
7.
Zurück zum Zitat Terazono K, Yamamoto H, Takasawa S et al (1988) A novel gene activated in regenerating islets. J Biol Chem 263(5):2111–2114PubMed Terazono K, Yamamoto H, Takasawa S et al (1988) A novel gene activated in regenerating islets. J Biol Chem 263(5):2111–2114PubMed
24.
Zurück zum Zitat Dahl U, Sjodin A, Semb H (1996) Cadherins regulate aggregation of pancreatic β-cells in vivo. Development 122(9):2895–2902PubMed Dahl U, Sjodin A, Semb H (1996) Cadherins regulate aggregation of pancreatic β-cells in vivo. Development 122(9):2895–2902PubMed
46.
Zurück zum Zitat Daha MR, Fearon DT, Austen KF (1976) C3 nephritic factor (C3NeF): stabilization of fluid phase and cell-bound alternative pathway convertase. J Immunol 116:1–7PubMed Daha MR, Fearon DT, Austen KF (1976) C3 nephritic factor (C3NeF): stabilization of fluid phase and cell-bound alternative pathway convertase. J Immunol 116:1–7PubMed
Metadaten
Titel
Cellular proliferation in mouse and human pancreatic islets is regulated by serpin B13 inhibition and downstream targeting of E-cadherin by cathepsin L
verfasst von
Chi-Wen Lo
Yury Kryvalap
Tzong-jen Sheu
Ching-Ho Chang
Jan Czyzyk
Publikationsdatum
01.03.2019
Verlag
Springer Berlin Heidelberg
Erschienen in
Diabetologia / Ausgabe 5/2019
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-019-4834-0

Weitere Artikel der Ausgabe 5/2019

Diabetologia 5/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.